As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
January 13, 2025 23:00 ET | Source: HUTCHMED (China) Limited — Indication expands to include treatment-naïve patients — — The 2021…
December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected…